US-based SP Industries acquired the sterile filling line assets of Spain-based i-Dositecno.
SP Industries (SP), a PA-based designer and manufacturer of laboratory equipment, pharmaceutical fill/finish manufacturing solutions, laboratory supplies, and glassware, announced in an Oct. 28, 2019 press release that it acquired the assets of privately held i-Dositecno, a global provider of sterile filling lines for pharmaceutical, cosmetic, and ophthalmic applications located in Mataro, Spain.
“i-Dositecno has a well-earned reputation for producing high quality, fill/finish equipment complemented by strong software engineering capabilities and innovative servicing and support,” stated SP CEO Brian Larkin in the release. He said that the i-Dositecno’s portfolio, engineering expertise, and liquid filling capabilities complement SP’s freeze dryers and aseptic vial processing lines.
“As biological drug development and treatment protocols have become more specialized, we expect short-run aseptic liquid filling to continue to drive pharmaceutical growth,” said Larkin in the release. “With the addition of i-Dositecno to our SP brand, we now join a very select group of manufacturers with the capability to provide full lines. And, while SP has traditionally had a stronger equipment footprint in the United States, i-Dositecno’s efforts and success have primarily been within Europe and Asia. These relationships, as well as the addition of a Spain location to our current UK manufacturing within Europe, provide significant opportunity to better serve the worldwide market. Key manufacturing, engineering, sales, and service personnel from i-Dositecno have joined the SP team to assure continuity in operations and service. Oriol Casoliva, founder and past CEO of i-Dositecno, will join SP’s Executive Leadership Team, and we look forward to benefiting from his vision and depth of knowledge in maximizing i-Dositecno and SP’s performance within the aseptic pharmaceutical manufacturing space.”
Source: SP Industries
FDA Approves Novartis Oral Treatment for Adults with C3 Glomerulopathy
March 25th 2025Fabhalta (iptacopan) received a positive opinion for treatment of C3G from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and has been approved twice before by FDA.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.